Alkermes (ALKS) Operating Leases (2019 - 2026)
Alkermes' (ALKS) quarterly Operating Leases came in at $62.0 million in Q2 2026, down 6.4% year-over-year from $66.2 million in Q2 2025, and down 2.78% quarter-over-quarter from $63.7 million in Q1 2026.
Analysis
Alkermes (ALKS) Operating Leases (2019 - 2026) Analysis & Trends
Alkermes (ALKS) has reported Operating Leases for 8 consecutive years, with $62.0 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Operating Leases fell 6.4% year-over-year to $62.0 million in Q2 2026; TTM through Jun 2026 was $62.0 million, a 6.4% decrease from a year earlier, with the FY2025 full-year figure at $63.3 million, down 8.82% from the prior year.
- Operating Leases was $62.0 million for Q2 2026 at Alkermes, down from $63.7 million in the prior quarter.
- Over five years, Operating Leases peaked at $104.0 million in Q1 2022 and troughed at $62.0 million in Q2 2026.
- A 5-year average of $76.3 million and a median of $73.3 million in 2024 frame the typical range for Operating Leases.
- Across the five-year window, Operating Leases dropped 26.76% in 2022 and fell 0.76% in 2023, its largest moves.
- Over 5 years, Operating Leases stood at $76.3 million in 2022, then declined by 0.76% to $75.7 million in 2023, then fell by 8.37% to $69.4 million in 2024, then fell by 8.82% to $63.3 million in 2025, then slipped by 2.02% to $62.0 million in 2026.
- The last three Operating Leases figures came in at $62.0 million (Q2 2026), $63.7 million (Q1 2026), and $63.3 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.03 Bn | 625.27 Bn | 17.26 Bn |
| 2 | AbbVie | 441.99 Bn | 435.42 Bn | 12.70 Bn |
| 3 | Merck | 366.30 Bn | 359.16 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.55 Bn | 258.86 Bn | 11.24 Bn |
| 5 | Pfizer | 159.14 Bn | 147.45 Bn | 10.94 Bn |
| 6 | Sanofi | 52.40 Bn | 45.02 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 44.13 Bn | 44.13 Bn | - |
| 8 | Incyte | 25.53 Bn | 20.99 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.51 Bn | 18.85 Bn | 683.80 Mn |
| 10 | Alkermes | 7.56 Bn | 6.91 Bn | 397.90 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 61.98 Mn |
| Mar 31, 2026 | 63.75 Mn |
| Dec 31, 2025 | 63.25 Mn |
| Sep 30, 2025 | 64.97 Mn |
| Jun 30, 2025 | 66.22 Mn |
| Mar 31, 2025 | 67.81 Mn |
| Dec 31, 2024 | 69.37 Mn |
| Sep 30, 2024 | 71.03 Mn |
| Jun 30, 2024 | 72.54 Mn |
| Mar 31, 2024 | 74.10 Mn |
| Dec 31, 2023 | 75.71 Mn |
| Sep 30, 2023 | 78.55 Mn |
| Jun 30, 2023 | 82.34 Mn |
| Mar 31, 2023 | 86.11 Mn |
| Dec 31, 2022 | 76.29 Mn |
| Sep 30, 2022 | 95.73 Mn |
| Jun 30, 2022 | 99.83 Mn |
| Mar 31, 2022 | 104.01 Mn |
| Dec 31, 2021 | 104.16 Mn |
| Sep 30, 2021 | 107.86 Mn |